Melanotan 1

Melanotan 1

$55.00

Melanotan 1 (MT-1), also known as afamelanotide, is a synthetic analog of α-melanocyte stimulating hormone (α-MSH) designed for enhanced stability and potency. This linear peptide selectively activates melanocortin-1 receptors (MC1R) to stimulate melanogenesis without the broader effects seen with other melanocortin receptor agonists. Originally developed for photoprotection research, MT-1 has revealed additional anti-inflammatory and tissue-protective properties that continue to expand its research applications.

Each vial contains pure, lyophilized powder for reconstitution. This product is exclusively for laboratory research and not for human or animal use.

Overview

Melanotan 1 represents a targeted approach to melanocortin receptor activation. Unlike its cyclic cousin Melanotan 2, MT-1 maintains a linear structure that provides selective MC1R activation, making it ideal for research focused on melanogenesis and photoprotection without unwanted side effects. This selectivity has made MT-1 particularly valuable in dermatological research, where it serves as a model compound for understanding UV protection mechanisms and melanin biology. Beyond skin pigmentation, emerging research reveals MT-1’s anti-inflammatory properties and potential neuroprotective effects.

This product is strictly for research purposes only. Not approved for human or animal use.

Key Characteristics

MOLECULAR PROFILE

Formula: C78H111N21O19

Weight: 1646.85 g/mol

CAS: 75921-69-6

Structure: Linear 13-amino acid peptide

PHYSICAL PROPERTIES

Form: White to off-white lyophilized powder

Solubility: Readily dissolves in water

Selectivity: High MC1R selectivity

Storage: Keep refrigerated 36‑46 °F (2‑8 °C)

How It Works

MT-1’s selective mechanism provides targeted biological effects:

Primary Mechanisms

MC1R Activation

Selectively binds to melanocortin-1 receptors on melanocytes

cAMP Signaling

Increases intracellular cAMP, activating protein kinase A

MITF Activation

Upregulates microphthalmia-associated transcription factor

Melanogenesis

Stimulates tyrosinase and other melanogenic enzymes

Protective Mechanisms

UV Protection

Enhanced melanin production provides natural photoprotection

DNA Repair

May enhance nucleotide excision repair mechanisms

Anti-inflammatory

Reduces inflammatory cytokine production

Research Findings

MT-1 research has revealed diverse applications beyond pigmentation:

Photoprotection Studies

Primary research focus on UV protection:

Increased melanin density without UV exposure
Reduced UV-induced DNA damage markers
Protection in photosensitivity disorder models
Sustained protective effects after discontinuation

Anti-inflammatory Effects

Emerging immunomodulatory properties:

Reduced TNF-α and IL-1β production
Suppression of NF-κB activation
Protection in inflammatory disease models
Potential in autoimmune research

Neuroprotective Research

Unexpected central nervous system effects:

Protection against oxidative stress in neurons
Reduced neuroinflammation markers
Potential in neurodegenerative disease models
Improved outcomes in stroke models

Clinical Research Applications

Translational research findings:

Erythropoietic protoporphyria studies
Polymorphous light eruption research
Vitiligo repigmentation investigations
Solar urticaria protection studies

Potential Side Effects in Research

MT-1 demonstrates a favorable safety profile with selective receptor targeting:

Mild Nausea

Transient gastrointestinal effects in some subjects

Facial Flushing

Temporary vasodilation effects

Fatigue

Mild tiredness reported in some studies

Pigmentation Changes

Expected darkening of skin and melanocytic nevi

MT-1’s MC1R selectivity minimizes off-target effects seen with broader melanocortin agonists.

IMPORTANT: This product is exclusively for laboratory research purposes and is not approved for human or veterinary use.

References

  1. Polańska A. Afamelanotide in protoporphyria and other skin diseases: comprehensive review. Skin Health Dis. 2024;4(2):e102-e110.
  2. Resnik SR, Targett D, Resnik BI. Into the light: afamelanotide and the treatment of erythropoietic protoporphyria in the United States. J Drugs Dermatol. 2023;22(9):941-949.
  3. Leaf RK, et al. Afamelanotide for treatment of the protoporphyrias: impact on quality of life and laboratory parameters in a US cohort. Life (Basel). 2024;14(6):689.
  4. Wensink D, Wagenmakers M, Langendonk JG. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert Rev Clin Pharmacol. 2021;14(2):151-160.
  5. Langendonk JG, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;372(20):1909-1917.
  6. Böhm M, Bodó E, Funk W, Paus R. α-Melanocyte-stimulating hormone: a protective peptide against chemotherapy-induced hair follicle damage? Br J Dermatol. 2014;170(4):956-960.

Third-Party Lab Tested

View our independent laboratory test certificate showing purity and composition analysis.


📋 View Test Certificate →

Weight N/A
Dimensions N/A
Size

10mg
SKU: OATH-MELANOTAN-1 Category: Tags: ,
Lab Tested and Shipped from the USA
Free Bacteriostatic Water
Free Shipping on Orders Over $200
The Purest Peptides. Period.
Updating…
Cart Close
  • No products in the cart.

Continue shopping